Antibiotic Disincentives? Medicare Decisions Underscore Limits Of Add-On Payments
CMS disappointed stakeholders looking for antibiotic payment incentives from Medicare with two recent decisions. One was to withhold new technology add-on payments from Dalvance and the other to allow existing NTAP benefits for Dificid to expire.
You may also be interested in...
Dalvance Approval Is Durata’s GAIN: First Test Of FDA’s Antibiotics Incentives
Durata has honor of having first drug approved under Qualified Infectious Disease Product designation and gains the benefits of an added five years of market exclusivity.
Optimer’s Dificid Gets Medicare Payment “Add-On” For Hospital Patients
In a rare application of its Medicare “new technology add-on payments” policy to drugs, the Centers for Medicare and Medicaid Services announced it will supplement reimbursement to hospitals for the oral antibiotic Deficid and methotrexate toxicity antidote Voraxaze.
Medicare Seeks Input On Dispute Resolution, Civil Penalties For Rx Pricing Program
Calculating a ‘fair price’ for new versions of already negotiated moiety is also one of several that CMS is requesting input on in its recently released initial guidance on the negotiation program.